IMMP vs. AKBA, DSGN, EPIX, EBS, ALDX, PYXS, XBIT, OMER, TSVT, and GTHX
Should you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Akebia Therapeutics (AKBA), Design Therapeutics (DSGN), ESSA Pharma (EPIX), Emergent BioSolutions (EBS), Aldeyra Therapeutics (ALDX), Pyxis Oncology (PYXS), XBiotech (XBIT), Omeros (OMER), 2seventy bio (TSVT), and G1 Therapeutics (GTHX). These companies are all part of the "pharmaceutical preparations" industry.
Akebia Therapeutics (NASDAQ:AKBA) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
Akebia Therapeutics received 100 more outperform votes than Immutep when rated by MarketBeat users. However, 72.43% of users gave Immutep an outperform vote while only 63.96% of users gave Akebia Therapeutics an outperform vote.
In the previous week, Akebia Therapeutics had 2 more articles in the media than Immutep. MarketBeat recorded 7 mentions for Akebia Therapeutics and 5 mentions for Immutep. Akebia Therapeutics' average media sentiment score of 0.48 beat Immutep's score of 0.46 indicating that Immutep is being referred to more favorably in the news media.
Akebia Therapeutics has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.
Immutep has lower revenue, but higher earnings than Akebia Therapeutics.
Immutep has a net margin of 0.00% compared to Immutep's net margin of -22.99%.
Akebia Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 334.78%. Immutep has a consensus target price of $8.50, suggesting a potential upside of 185.23%. Given Immutep's higher possible upside, equities analysts plainly believe Akebia Therapeutics is more favorable than Immutep.
33.9% of Akebia Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Immutep shares are held by institutional investors. 3.8% of Akebia Therapeutics shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Akebia Therapeutics and Immutep tied by winning 7 of the 14 factors compared between the two stocks.
Get Immutep News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
